The Goldman Sachs Group Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $43.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target lowered by research analysts at The Goldman Sachs Group from $48.00 to $43.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target suggests a potential upside of 264.84% from the company’s previous close.

A number of other research firms have also recently commented on DAWN. Needham & Company LLC reiterated a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Bank of America lowered their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN traded down $0.26 during mid-day trading on Monday, reaching $11.79. 315,032 shares of the company’s stock were exchanged, compared to its average volume of 1,061,818. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -11.44 and a beta of -1.46. Day One Biopharmaceuticals has a 52 week low of $11.13 and a 52 week high of $18.07. The firm has a 50-day moving average price of $12.63 and a two-hundred day moving average price of $13.64.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the completion of the sale, the insider now owns 1,034,015 shares of the company’s stock, valued at $13,762,739.65. This represents a 2.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 8.40% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Turn Management LLC bought a new stake in Day One Biopharmaceuticals in the third quarter valued at approximately $13,204,000. GSA Capital Partners LLP bought a new position in shares of Day One Biopharmaceuticals during the third quarter valued at approximately $825,000. Algert Global LLC raised its holdings in shares of Day One Biopharmaceuticals by 248.8% during the third quarter. Algert Global LLC now owns 71,487 shares of the company’s stock valued at $996,000 after acquiring an additional 50,990 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $866,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Day One Biopharmaceuticals by 14.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock valued at $7,069,000 after acquiring an additional 64,700 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.